Meeting
2022 ASCO Annual Meeting
Clinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting.
Authors
Adriana Matutino Kahn
Yale School of Medicine, New Haven, CT
Adriana Matutino Kahn , Curtis Perry , Katrina Etts , Harriet M. Kluger , Mario Sznol
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9555)
DOI
10.1200/JCO.2022.40.16_suppl.9555
Abstract #
9555
Poster Bd #
148
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Real-world time to next treatment (TTNT) for first-line (1L) targeted and immuno-oncology therapies for BRAF-mutated metastatic melanoma (MM) by lactate dehydrogenase (LDH) level.
First Author: Jason J. Luke
Poster
2018 ASCO Annual Meeting
Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma.
First Author: Cathy Yi Xia
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Real world treatment patterns of first-line combination therapies among BRAF+ metastatic melanoma patients.
First Author: Sameer Ghate
Poster
2022 ASCO Genitourinary Cancers Symposium
Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).
First Author: Vishal Navani